Methods for treatment of diseases
The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.
1. A method of treating a human patient suffering from a condition that is treatable with a superoxide dismutase mimetic corresponding to Formula (GC4419) below, the condition comprising any selected from the group consisting of tissue damage or toxicity resulting from radiation therapy, chemotherapy, or a combination thereof, pancreatitis, colitis, inflammatory bowel disease, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and asthma, the method comprising parenterally administering to the patient 75 mg to 450 mg of the superoxide dismutase mimetic corresponding to Formula (GC4419):
wherein X and Y are independently neutral or negatively-charged ligands.
2. The method of claim 1 , wherein the method comprises administering to the patient the superoxide dismutase mimetic to provide an exposure as measured by an area under the curve (AUC) of at least 4,000 ng-h/mL as calculated from measurement of the superoxide dismutase mimetic concentration in the patient's plasma.
3. The method of claim 1 , wherein the superoxide dismutase mimetic is administered intravenously.
4. The method of claim 1 , wherein the superoxide dismutase mimetic is administered as a pharmaceutical composition comprising the superoxide dismutase mimetic corresponding to Formula (GC4419) and a pharmaceutically acceptable carrier.
5. The method of claim 1 , wherein the superoxide dismutase mimetic is administered in the form of a unit dose formulation.
6. The method of claim 1 , wherein the superoxide dismutase mimetic is dissolved in a solution comprising 0.25 mg/mL to 3.5 mg/mL superoxide dismutase mimetic and contained in an IV bag.
7. The method of claim 1 , wherein X and Y are independently selected from monodentate ligands.
8. The method of claim 1 , wherein X and Y are independently selected from the group consisting of aquo ligands, halo ligands, carboxylate ligands, and bicarbonate ligands.
9. The method of claim 1 , wherein X and Y are chloro ligands.
10. The method of claim 1 , wherein the method comprises parenterally administering to the patient at least 100 mg of the superoxide dismutase mimetic.
11. The method of claim 1 , wherein the method comprises administering the superoxide dismutase mimetic to the patient within a period of 45 minutes.
12. The method of claim 1 , wherein the method comprises administering the superoxide dismutase mimetic to the patient witinh a period of 60 minutes.
13. The method of claim 1 , wherein the method comprises administering the superoxide dismutase mimetic to the patient at a rate of 100 mg/hr.
14. The method of claim 1 , wherein the method comprises administering the superoxide dismutase mimetic to the patient at a rate of 200 mg/hr.
15. The method of claim 1 , wherein the method comprises administering the superoxide dismutase mimetic to the patient at a rate of 450 mg/hr.
16. The method of claim 1 , wherein the method comprises treating a tissue damage that is treatable with the superoxide dismutase mimetic corresponding to Formula (GC4419) in a patient suffering from cancer.
17. The method of claim 1 , wherein the method comprises reducing tissue damage or toxicity resulting from radiation therapy, chemotherapy or a combination thereof.
18. The method of claim 1 , wherein the superoxide dismutase mimetic is administered to the patient prior to or simultaneous with the radiation therapy or chemotherapy.
19. The method of claim 1 , wherein the superoxide dismutase mimetic is administered to the patient prior to, but not after, the radiation therapy or chemotherapy.
20. The method of claim 1 wherein the superoxide dismutase mimetic is administered to the patient at least 30 minutes prior to the radiation therapy or chemotherapy.
21. The method of claim 1 , wherein the superoxide dismutase mimetic is administered to the patient after the radiation therapy or chemotherapy.
22. The method of claim 1 , wherein the superoxide dismutase mimetic is administered to the patient up to twelve weeks after the radiation therapy or chemotherapy.